Results 51 to 60 of about 15,884 (195)
The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. [PDF]
, 2014 BACKGROUND: To date no network meta-analysis (NMA) has accounted for baseline variations in viral load when assessing the relative efficacy of interventions for chronic hepatitis B (CHB).
A Wiens +50 more
core +4 more sources
Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
Hepatology Research, EarlyView.Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa +2 more
wiley +1 more source
HIV Medicine, EarlyView.Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang +15 more
wiley +1 more source
Journal of the Formosan Medical Association, 2014 Several anti-viral drugs are approved for the treatment of hepatitis B virus (HBV) infection. However, whether quantitative hepatitis B surface antigen (qHBsAg) can predict the therapeutic response during long-term entecavir treatment remains unclear ...
Chia-Chi Wang +4 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye +9 more
wiley +1 more source
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]
, 2019 Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M. +7 more
core +1 more source
Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy [PDF]
, 2010 Recently, we reported on three patients with chronic hepatitis B virus (HBV) infection for whom adefovir (ADF) therapy virologically failed, most likely due to a preexisting rtI233V HBV polymerase mutation.
Funk, Anneke +6 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham +4 more
wiley +1 more source
Tenofovir as rescue therapy following clinical failure to lamivudine in severe acute hepatitis B [PDF]
, 2013 Acute hepatitis B (AHB) is a self-limiting condition in more than 95% of cases. Treatment is however recommended in patients with severe AHB (
Borg, Elaine +4 more
core +2 more sources
Journal of Medical Virology, Volume 98, Issue 5, May 2026.ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo +12 more
wiley +1 more source